TVRD · CIK 1346830
What Tvardi Therapeutics, Inc. told the SEC could break it.
Tvardi's disclosures are those of an early-stage, pre-revenue drug developer years away from any product. It has never generated product revenue, carried a $110.5 million accumulated deficit at year-end 2025, and all of its candidates are still in preclinical or early clinical development — so its future hinges on clearing the lengthy, uncertain FDA and foreign approval process and then securing adequate coverage and reimbursement from Medicare, Medicaid and commercial payors. It owns no manufacturing facilities and depends on third-party contract manufacturers and CROs worldwide for its drug supply, with no control over their quality or regulatory compliance. It also flags U.S.–China trade-policy risk, where further tariffs or retaliatory measures could disrupt access to the active pharmaceutical ingredients and raw materials its candidates rely on.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA/foreign approval and third-party-payor reimbursementmedium
Tvardi's candidates require lengthy, uncertain FDA and foreign regulatory approval, and future commercial success depends on adequate coverage/reimbursement from Medicare, Medicaid and commercial payors — both significant regulatory hurdles to revenue.
“Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.”
SEC filing →As of 2026 - tariffs / China trade restrictions affecting API and raw-material supplylow
Tvardi flags significant US-China trade-policy uncertainty: further tariffs could affect imports of APIs used in its product candidates, and Chinese retaliatory trade measures could restrict access to raw materials critical to its drug candidates.
“It is possible further tariffs may be imposed that could affect imports of APIs used in our product candidates or any other potential future product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials used”
SEC filing →As of 2026
Supplier concentration
- reliance on third-party CROs/CDMOs for manufacturing (owns no manufacturing facilities)medium
Tvardi owns no manufacturing facilities and relies on third-party contract manufacturers (CDMOs) and CROs globally for its preclinical and clinical product supply, with no assurance of adequate quantity/quality and no control over those manufacturers' regulatory compliance.
“We rely on third-party contract manufacturers to manufacture our product candidates for preclinical studies and clinical trials. We do not own manufacturing facilities for producing any clinical trial product supplies.”
SEC filing →As of 2026
Other disclosures
- clinical-stage, pre-revenue; $110.5M accumulated deficit; candidates preclinical/early-clinicallow
Tvardi has never generated product revenue, had a $110.5M accumulated deficit at year-end 2025, and all its candidates (TTI-101, TTI-109) are in preclinical/early-clinical development — needing substantial further financing and years before any potential commercialization.
“All of our product candidates are still in preclinical and early clinical development and may be unable to obtain regulatory approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities nec”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch